Biotechnological companies using AI
Takeda Pharmaceutical has entered into a multi--year collaboration with Iambic Therapeutics, valued at over $1.7 billion, to accelerate small--molecule development in oncology, inflammation, and gastrointestinal diseases. This partnership, announced on February 9, 2026, underscores Takeda's strategic integration of AI into its research and development efforts, aiming to expedite drug discovery and target complex diseases more precisely.